Statements

Find out what Breast Cancer Care is saying about the latest drug treatments, research papers and health policy issues.

If you’re working on a story and need an expert quote, call us on 0345 092 0807 (out of hours 07702 901 334).

Responding to NICE’s draft decision not to recommend fulvestrant (Faslodex) for use by the NHS in England for the treatment of ER positive...

Responding to the news that immune cell ‘hotspots’ could help identify women at high risk of relapsing breast cancer, Jane Murphy, Clinical...

Responding to a new study, published in the journal Clinical Chemistry, that suggests the prospect of further personalisation of treatment for...

Responding to the Cancer Patient Experience Survey, released today, David Crosby, Director of Services and Engagement at Breast Cancer Care, says:...

Responding to a new study that suggests menopausal symptoms often linked to tamoxifen* also occurred when women were taking a placebo drug, Carolyn...

Responding to the latest ONS one and five-year survival figures, and the predicted 10-year survival figures for breast cancer in England, Gunes Kalkan,...

Responding to the decision from NICE, announced today (Thursday 15 June), that trastuzumab emtansine (Kadcyla)* is approved for use on the NHS in England...

Responding to the decision from NICE announced today (Thursday 15 June) that trastuzumab emtansine (Kadcyla)* is approved for use on the NHS in England,...

Responding to the Scottish Medicines Consortium decision that pertuzumab (Perjeta)* in combination with two other treatments - trastuzumab and docetaxel...

Responding to expert comment from the American Society of Clinical Oncology conference in Chicago - suggesting that three-quarters of cancer patients in...

Sign up for our newsletter